Abstract
Irritable bowel syndrome is a group of functional gastrointestinal disorders with not yet fully clarified etiology. Recent evidence suggesting that mast cells may play a central role in the pathogenesis of irritable bowel syndrome paves the way for agents targeting histamine receptors as a potential therapeutic option in clinical treatment. In this review, the role of histamine and histamine receptors is debated. Moreover, the clinical evidence of anti-histamine therapeutics in irritable bowel syndrome is discussed.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Medizin |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
URN: | urn:nbn:de:bvb:19-epub-51200-0 |
ISSN: | 2093-0879 |
Sprache: | Englisch |
Dokumenten ID: | 51200 |
Datum der Veröffentlichung auf Open Access LMU: | 14. Jun. 2018, 09:45 |
Letzte Änderungen: | 04. Nov. 2020, 13:29 |